As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The ASRA Division of Hetero Healthcare is focused on providing therapeutic solutions across pain management, inflammation, musculoskeletal disorders, nutritional support, and associated healthcare needs. Its portfolio is designed to address conditions that can affect mobility, comfort, and overall quality of life, supporting healthcare professionals in the management of both acute and chronic patient needs.
With an emphasis on comprehensive patient care, the division brings together therapies that support the management of pain and inflammation, bone and joint health, muscle-related conditions, and nutritional deficiencies. This integrated approach enables ASRA to cater to a broad spectrum of clinical requirements while keeping patient well-being at the centre of its therapeutic focus.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and responsible healthcare, the ASRA Division continues to strengthen its portfolio with dependable therapeutic options. Through a combination of established therapies and evolving healthcare solutions, ASRA strives to support better clinical management and contribute to improved patient outcomes.
View by-
